BriaCell Therapeutics (BCTX) Stock Price, News & Analysis

Company Overview

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.

Key Stats

• Today's Range: $3.92 to $4.13
• 50-Day Range: $3.18 to $6.03
• 52-Week Range: $3.00 to $36.60
• Volume: 412,432 shs
• Average Volume: 483,483 shs
• Market Capitalization: $14.84 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $32.00
• Consensus Rating: Buy

BriaCell Therapeutics Stock Analysis - MarketRank™

BriaCell Therapeutics scored higher than 34% of companies evaluated by MarketBeat, and ranked 831st out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

BriaCell Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

BriaCell Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for BriaCell Therapeutics are expected to grow in the coming year, from ($2.45) to ($1.47) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of BriaCell Therapeutics is -0.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of BriaCell Therapeutics is -0.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

5.96% of the float of BriaCell Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

BriaCell Therapeutics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in BriaCell Therapeutics has recently increased by 7.82%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

BriaCell Therapeutics does not currently pay a dividend.

Dividend Growth

BriaCell Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

5.96% of the float of BriaCell Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

BriaCell Therapeutics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in BriaCell Therapeutics has recently increased by 7.82%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.0 / 5
• News Sentiment: -0.46

News Sentiment

BriaCell Therapeutics has a news sentiment score of -0.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.81 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for BriaCell Therapeutics this week, compared to 1 article on an average week.

Search Interest

5 people have searched for BCTX on MarketBeat in the last 30 days. This is an increase of 67% compared to the previous 30 days.

MarketBeat Follows

3 people have added BriaCell Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, BriaCell Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 5.73% of the stock of BriaCell Therapeutics is held by insiders.

Percentage Held by Institutions

Only 15.42% of the stock of BriaCell Therapeutics is held by institutions.

BCTX Stock Analysis - Frequently Asked Questions

How have BCTX shares performed this year?

BriaCell Therapeutics' stock was trading at $8.4750 at the start of the year. Since then, BCTX stock has decreased by 52.8% and is now trading at $4.00.
View the best growth stocks for 2025 here.

How were BriaCell Therapeutics' earnings last quarter?

BriaCell Therapeutics Corp. (NASDAQ:BCTX) issued its quarterly earnings results on Monday, March, 17th. The company reported ($2.33) earnings per share for the quarter, missing analysts' consensus estimates of ($1.94) by $0.39.

When did BriaCell Therapeutics' stock split?

BriaCell Therapeutics shares reverse split on the morning of Wednesday, January 29th 2025. The 1-15 reverse split was announced on Friday, January 3rd 2025. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, January 28th 2025. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

When did BriaCell Therapeutics IPO?

BriaCell Therapeutics (BCTX) raised $15 million in an initial public offering on Wednesday, February 24th 2021. The company issued 3,300,000 shares at $4.25-$5.00 per share. ThinkEquity (a division of Fordham Financial Management) served as the underwriter for the IPO.

How do I buy shares of BriaCell Therapeutics?

Shares of BCTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of BriaCell Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that BriaCell Therapeutics investors own include Invesco QQQ (QQQ), SPDR Dow Jones Industrial Average ETF Trust (DIA), SPDR S&P 500 ETF Trust (SPY), Meta Platforms (META), Plug Power (PLUG), Micron Technology (MU) and Permian Basin Royalty Trust (PBT).

Company Calendar

• Last Earnings: 3/17/2025
• Today: 5/02/2025
• Next Earnings (Estimated): 6/13/2025
• Fiscal Year End: 7/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:BCTX
• CIK: 1610820
• Web: www.briacell.com
• Phone: (604) 921-1810
• Fax: 604-921-1898
• Employees: 8
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $32.00
• High Stock Price Target: $32.00
• Low Stock Price Target: $32.00
• Potential Upside/Downside: +700.0%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($5.03)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-4,790,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -191.19%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.65
• Quick Ratio: 1.65

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($2.20) per share
• Price / Book: -1.82

Miscellaneous

• Outstanding Shares: 3,709,000
• Free Float: 3,496,000
• Market Cap: $14.84 million
• Optionable: Optionable
• Beta: 1.34